Cargando…
The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease
The accumulation and aggregation of alpha-synuclein (α-Syn) are pathological processes associated with Parkinson’s disease, indicating that the regulation of protein is a crucial etiopathological mechanism. Interestingly, human serum and cerebrospinal fluid contain autoantibodies that recognize α-Sy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526238/ https://www.ncbi.nlm.nih.gov/pubmed/37759704 http://dx.doi.org/10.3390/biom13091303 |
_version_ | 1785110974416551936 |
---|---|
author | Albus, Alexandra Kronimus, Yannick Burg-Roderfeld, Monika van der Wurp, Hendrik Willbold, Dieter Ziehm, Tamar Dodel, Richard Ross, Jean Alexander |
author_facet | Albus, Alexandra Kronimus, Yannick Burg-Roderfeld, Monika van der Wurp, Hendrik Willbold, Dieter Ziehm, Tamar Dodel, Richard Ross, Jean Alexander |
author_sort | Albus, Alexandra |
collection | PubMed |
description | The accumulation and aggregation of alpha-synuclein (α-Syn) are pathological processes associated with Parkinson’s disease, indicating that the regulation of protein is a crucial etiopathological mechanism. Interestingly, human serum and cerebrospinal fluid contain autoantibodies that recognize α-Syn. This potentially demonstrates an already existing, naturally decomposing, and protective system. Thus, quantitative or qualitative alterations, such as the modified antigen binding of so-called naturally occurring autoantibodies against α-Syn (nAbs-α-Syn), may induce disease onset and/or progression. We investigated the serum titers and binding characteristics of nAbs-α-Syn in patients suffering from sporadic Parkinson’s disease (n = 38), LRRK2 mutation carriers (n = 25), and healthy controls (n = 22). Methods: Titers of nAbs-α-Syn were assessed with ELISA and binding affinities and kinetics with SPR. Within the patient cohort, we discriminated between idiopathic and genetic (LRRK2-mutated) variants. Results: ELISA experiments revealed no significant differences in nAbs-α-Syn serum titers among the three cohorts. Moreover, the α-Syn avidity of nAbs-α-Syn was also unchanged. Conclusions: Our findings indicate that nAbs-α-Syn concentrations or affinities in healthy and diseased persons do not differ, independent of mutations in LRRK2. |
format | Online Article Text |
id | pubmed-10526238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105262382023-09-28 The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease Albus, Alexandra Kronimus, Yannick Burg-Roderfeld, Monika van der Wurp, Hendrik Willbold, Dieter Ziehm, Tamar Dodel, Richard Ross, Jean Alexander Biomolecules Brief Report The accumulation and aggregation of alpha-synuclein (α-Syn) are pathological processes associated with Parkinson’s disease, indicating that the regulation of protein is a crucial etiopathological mechanism. Interestingly, human serum and cerebrospinal fluid contain autoantibodies that recognize α-Syn. This potentially demonstrates an already existing, naturally decomposing, and protective system. Thus, quantitative or qualitative alterations, such as the modified antigen binding of so-called naturally occurring autoantibodies against α-Syn (nAbs-α-Syn), may induce disease onset and/or progression. We investigated the serum titers and binding characteristics of nAbs-α-Syn in patients suffering from sporadic Parkinson’s disease (n = 38), LRRK2 mutation carriers (n = 25), and healthy controls (n = 22). Methods: Titers of nAbs-α-Syn were assessed with ELISA and binding affinities and kinetics with SPR. Within the patient cohort, we discriminated between idiopathic and genetic (LRRK2-mutated) variants. Results: ELISA experiments revealed no significant differences in nAbs-α-Syn serum titers among the three cohorts. Moreover, the α-Syn avidity of nAbs-α-Syn was also unchanged. Conclusions: Our findings indicate that nAbs-α-Syn concentrations or affinities in healthy and diseased persons do not differ, independent of mutations in LRRK2. MDPI 2023-08-25 /pmc/articles/PMC10526238/ /pubmed/37759704 http://dx.doi.org/10.3390/biom13091303 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Albus, Alexandra Kronimus, Yannick Burg-Roderfeld, Monika van der Wurp, Hendrik Willbold, Dieter Ziehm, Tamar Dodel, Richard Ross, Jean Alexander The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title_full | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title_fullStr | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title_full_unstemmed | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title_short | The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease |
title_sort | avidity of autoreactive alpha-synuclein antibodies in leucine-rich repeat kinase 2 mutation carriers is not altered compared to healthy controls or patients with parkinson’s disease |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526238/ https://www.ncbi.nlm.nih.gov/pubmed/37759704 http://dx.doi.org/10.3390/biom13091303 |
work_keys_str_mv | AT albusalexandra theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT kronimusyannick theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT burgroderfeldmonika theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT vanderwurphendrik theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT willbolddieter theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT ziehmtamar theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT dodelrichard theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT rossjeanalexander theavidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT albusalexandra avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT kronimusyannick avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT burgroderfeldmonika avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT vanderwurphendrik avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT willbolddieter avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT ziehmtamar avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT dodelrichard avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease AT rossjeanalexander avidityofautoreactivealphasynucleinantibodiesinleucinerichrepeatkinase2mutationcarriersisnotalteredcomparedtohealthycontrolsorpatientswithparkinsonsdisease |